{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-005312","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.516779+00:00","generated_at":"2026-06-24T05:35:42.687571+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anika Q2 rev $39.7M (+4%); net loss ($2.8M) vs prior profit $6.5M","bullets":["Q2 revenue $39.7M (+4% YoY); OA Pain Mgmt $25.7M (+6%), Joint Preservation $12.1M (+2%).","Net loss ($2.8M) or ($0.20)/share vs prior net income $6.5M ($0.45); adjusted net loss ($1.6M) or ($0.12)/share.","Adjusted EBITDA $4.4M vs $6.1M; cash $91.4M, no debt.","X-Twist Fixation System FDA 510(k) clearance received; limited market release on schedule for 2H 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-005312","json":"https://secwatch.observer/filing/0001171843-22-005312.json","markdown":"https://secwatch.observer/filing/0001171843-22-005312.md","text":"https://secwatch.observer/filing/0001171843-22-005312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184322005312/0001171843-22-005312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184322005312/f8k_080322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:35:42.687571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}